# SEG P0 Source Closure Sprint Report

**Mode:** `CONTROLLED EVIDENCE CLOSURE EXECUTION`  
**Scope:** Drug HTML, OSCE Atlas, and PreTest only.  
**Prepared by:** **Manus AI**  
**Final status:** `SEG_P0_SOURCE_CLOSURE_SPRINT_COMPLETE`

## 1. Executive Decision

The P0 evidence-closure sprint is complete as a controlled review of evidence already present in the SEG workspace. None of the three P0 sources is approved for normalization. Each remains `BLOCKED_PENDING_EVIDENCE`; the sprint records closure findings and permitted next actions only.

```text
APPROVED_SOURCES = NONE
NORMALIZATION = BLOCKED_PENDING_APPROVED_SOURCE
P0_DECISIONS = NO_AUTOMATIC_APPROVAL
```

## 2. Source-by-Source Summary

| Source | Evidence found | Evidence missing | Blocking reasons | Final decision |
|---|---|---|---|---|
| Drug HTML | Retained static HTML artifact, checksum/structural observations, and local recovery continuity | Canonical title, owner, version/date, original locator, transformation history, copyright/license, educational and redistribution permissions, exact-artifact medication review, technical representation review | Identity is only partial; provenance is incomplete; rights are unavailable; medical and technical reviews are pending | `BLOCKED_PENDING_EVIDENCE` |
| OSCE Atlas | Recovered ZIP/container, associated text, validation notes, and 14 PNG members with inventory/hash observations | Authoritative atlas identity, owner/version/date/locator, text/image rights, per-image lineage, completeness against source, transformation history, medical, technical, visual-quality, and accessibility reviews | Package inventory does not establish authority or per-image rights/lineage; required clinical and visual/accessibility reviews are pending | `BLOCKED_PENDING_EVIDENCE` |
| PreTest | Recovered text representation, checksum/lineage observations, and recorded OCR/authoritative-PDF gap | Authoritative title, owner/version/date/locator, authoritative PDF/equivalent, complete OCR/transformation history, immutable comparison, completeness/numbering, rights, provenance, medical assessment, and technical review | Recovered representation cannot establish authoritative identity or completeness; rights and required reviews are pending | `BLOCKED_PENDING_EVIDENCE` |

## 3. Review Findings

### 3.1 Drug HTML

The retained artifact provides continuity and structural observations but not authoritative source identity or clinical validation. The exact representation requires medication-safety review for drug identity, dose statements, interactions, contraindications, omissions, ambiguity, and conflicts. It also requires a technical review of encoding, rendering, extraction boundaries, stable locators, and reproducibility.

**Next allowed action:** Request attributable owner/version/locator, rights, and provenance evidence for the exact artifact or authoritative source, then queue role-based medical and technical review while preserving the HTML unchanged.

### 3.2 OSCE Atlas

The recovered package establishes a retained container and a 14-PNG inventory, but it does not establish the authoritative atlas or image rights. Each image requires source-to-member lineage, rights applicability, and visual-quality/accessibility assessment before any governed use. OSCE clinical review and technical package review remain open.

**Next allowed action:** Request authoritative source and owner evidence, a text/image rights packet, per-image locators and transformation history, then reconcile each PNG and queue medical, technical, visual-quality, and accessibility review. The PNG set must not substitute for Clinical Images.

### 3.3 PreTest

The recovered text is an evidence representation with documented OCR and authoritative-PDF gaps. It must remain unchanged pending an authoritative comparison. Question-level clinical and assessment review, completeness/numbering reconciliation, and technical OCR/representation review cannot be completed on the current evidence alone.

**Next allowed action:** Request the authoritative PreTest PDF or independently verifiable equivalent, owner/version/date/locator evidence, and rights packet. Perform a read-only comparison and then queue assessment and technical review.

## 4. Governance Impact

This sprint does not alter the Master Source Registry, source approval states, evidence gates, professional-track assignments, or the normalization gate. It does not transform recovered material into approved medical content. The queue update is limited to the evidence status and closure notes for the three P0 rows.

## 5. Prohibited Actions Remaining

Normalization, Content Record creation, Zod or Prisma work, SQL, migrations, imports, activation, publication, learner exposure, database changes, application changes, OCR correction before evidence capture, Atlas record creation, content mapping, and any change to `APPROVED_SOURCES` remain prohibited.

## References

[1]: file:///home/ubuntu/seg-internship-output/SEG_EXTERNAL_EVIDENCE_COLLECTION_REPORT_v1.md "SEG External Evidence Collection Report v1"
[2]: file:///home/ubuntu/seg-internship-output/SEG_SOURCE_CLOSURE_DECISION_QUEUE.md "SEG Source Closure Decision Queue"
[3]: file:///home/ubuntu/seg-internship-output/SEG_EXTERNAL_EVIDENCE_ACQUISITION_TRACKER.md "SEG External Evidence Acquisition Tracker"
[4]: file:///home/ubuntu/seg-internship-output/SEG_DRUG_HTML_RECOVERY_STATUS.md "SEG Drug HTML Recovery Status"
[5]: file:///home/ubuntu/seg-internship-output/SEG_OSCE_ATLAS_RECOVERY_STATUS.md "SEG OSCE Atlas Recovery Status"
[6]: file:///home/ubuntu/seg-internship-output/SEG_PRETEST_RECOVERY_STATUS.md "SEG PreTest Recovery Status"

---

**SEG_P0_SOURCE_CLOSURE_SPRINT_COMPLETE**
